当前位置:首页 - 行情中心 - 药康生物(688046) - 财务分析 - 现金流量表

药康生物

(688046)

  

流通市值:72.32亿  总市值:72.32亿
流通股本:4.10亿   总股本:4.10亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金307,841,303.42125,542,405.66650,725,751.22405,979,174.95
  收到其他与经营活动有关的现金9,912,469.0316,144,303.7723,392,070.1714,498,168.81
  经营活动现金流入的平衡项目00.0100
  经营活动现金流入小计317,753,772.45141,686,709.44674,117,821.39420,477,343.76
  购买商品、接受劳务支付的现金90,518,048.1543,044,083.01134,141,161.24118,007,599.36
  支付给职工以及为职工支付的现金171,511,317.4499,705,079.68306,905,206.56230,281,997.01
  支付的各项税费11,210,555.782,613,044.4540,587,958.8333,082,044.75
  支付其他与经营活动有关的现金29,248,872.4723,052,108.03102,169,235.2355,006,662.35
  经营活动现金流出小计302,488,793.84168,414,315.17583,803,561.86436,378,303.47
  经营活动产生的现金流量净额平衡项目000-0.01
  经营活动产生的现金流量净额15,264,978.61-26,727,605.7390,314,259.53-15,900,959.72
二、投资活动产生的现金流量:
  取得投资收益收到的现金6,066,539.452,154,024.4423,360,314.7911,886,325.57
  处置固定资产、无形资产和其他长期资产收回的现金净额13,00013,000--
  收到的其他与投资活动有关的现金913,387,333.34373,242,333.341,895,315,833.551,409,770,981.39
  投资活动现金流入小计919,466,872.79375,409,357.781,918,676,148.341,421,657,306.96
  购建固定资产、无形资产和其他长期资产支付的现金71,418,745.6532,289,074.17113,677,403.3390,896,900.61
  投资支付的现金14,010,000-14,000,00114,000,000
  支付其他与投资活动有关的现金1,180,702,135.85720,000,0001,632,105,9001,263,875,664.47
  投资活动现金流出小计1,266,130,881.5752,289,074.171,759,783,304.331,368,772,565.08
  投资活动产生的现金流量净额-346,664,008.71-376,879,716.39158,892,844.0152,884,741.88
三、筹资活动产生的现金流量:
  取得借款收到的现金220,450,000119,450,00097,950,00067,950,000
  收到其他与筹资活动有关的现金11,249,600---
  筹资活动现金流入小计231,699,600119,450,00097,950,00067,950,000
  偿还债务支付的现金67,952,777.7867,950,00086,000,00076,063,305.56
  分配股利、利润或偿付利息支付的现金2,020,919.81613,696.380,114,031.867,314,042.98
  支付其他与筹资活动有关的现金11,302,726.934,101,292.3840,780,732.1429,523,502.35
  筹资活动现金流出小计81,276,424.5272,664,988.68206,894,763.94172,900,850.89
  筹资活动产生的现金流量净额150,423,175.4846,785,011.32-108,944,763.94-104,950,850.89
四、汇率变动对现金及现金等价物的影响1,744,503.74532,829.53959,889.98-1,355,366.52
五、现金及现金等价物净增加额-179,231,350.88-356,289,481.27141,222,229.58-69,322,435.25
  加:期初现金及现金等价物余额701,215,442.73701,225,470.73559,993,213.15559,993,213.15
  期末现金及现金等价物余额521,984,091.85344,935,989.46701,215,442.73490,670,777.9
补充资料:
  净利润70,905,477.14-109,819,819.3-
  资产减值准备8,308,552.96-21,644,970.29-
  固定资产和投资性房地产折旧35,748,942.78-69,890,289.2-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧35,748,942.78-69,890,289.2-
  无形资产摊销2,256,109.66-4,008,360.44-
  长期待摊费用摊销5,994,118.06-12,059,616.34-
  处置固定资产、无形资产和其他长期资产的损失25,422.09--12,516.02-
  公允价值变动损失-372,000.14--2,341,561.65-
  财务费用915,290.03--2,704,589.07-
  投资损失-1,351,054.93--8,003,815.54-
  递延所得税-2,807,207.92--5,339,895.82-
  其中:递延所得税资产减少-3,617,398.16--4,129,748.32-
    递延所得税负债增加810,190.24--1,210,147.5-
  存货的减少-8,045,852.22--7,104,922.03-
  经营性应收项目的减少-73,266,368.56--91,325,148.82-
  经营性应付项目的增加-39,999,279.4--27,480,862.13-
  其他1,908,565.55-2,977,476.74-
  不涉及现金收支的投资和筹资活动金额其他项目--5,131,149.03-
  现金的期末余额521,984,091.85-701,215,442.73-
  减:现金的期初余额701,215,442.73-559,993,213.15-
  现金及现金等价物的净增加额-179,231,350.88-141,222,229.58-
公告日期2025-08-232025-04-262025-04-262024-10-31
审计意见(境内)标准无保留意见
TOP↑